0001437749-24-011545.txt : 20240409 0001437749-24-011545.hdr.sgml : 20240409 20240409172020 ACCESSION NUMBER: 0001437749-24-011545 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240403 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240409 DATE AS OF CHANGE: 20240409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Clene Inc. CENTRAL INDEX KEY: 0001822791 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 852828339 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39834 FILM NUMBER: 24833583 BUSINESS ADDRESS: STREET 1: 6550 SOUTH MILLROCK DRIVE, SUITE G50 CITY: SALT LAKE CITY STATE: UT ZIP: 84121 BUSINESS PHONE: 801-676-9695 MAIL ADDRESS: STREET 1: 6550 SOUTH MILLROCK DRIVE, SUITE G50 CITY: SALT LAKE CITY STATE: UT ZIP: 84121 FORMER COMPANY: FORMER CONFORMED NAME: Chelsea Worldwide Inc. DATE OF NAME CHANGE: 20200827 8-K 1 clnn20240409_8k.htm FORM 8-K clnn20240409_8k.htm
false 0001822791 0001822791 2024-04-03 2024-04-03 0001822791 clnn:CommonStock00001ParValueCustomMember 2024-04-03 2024-04-03 0001822791 clnn:WarrantsToAcquireOnehalfOfOneShareOfCommonStockFor1150PerShareCustomMember 2024-04-03 2024-04-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 3, 2024
CLENE INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-39834
85-2828339
(State or other jurisdiction
(Commission File Number)
(IRS Employer
of incorporation)
  
Identification No.)
     
6550 South Millrock Drive, Suite G50
Salt Lake City, Utah
  
84121
(Address of principal executive offices)
  
(Zip Code)
(801) 676-9695
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Common Stock, $0.0001 par value
  
CLNN
  
The Nasdaq Capital Market
Warrants, to acquire one-half of one share of Common Stock for $11.50 per share
   CLNNW  
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
Item 1.01 Entry into a Material Definitive Agreement.
 
Previously, on October 5, 2023, Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”) announced a four-year, $45.1 million grant (“the NIH Grant”) from the National Institute of Health (“NIH”) to the Company, in collaboration with Colombia University (“Colombia”), the prime awardee, and Synapticure, a neurology specialty health clinic. The NIH Grant will support an Expanded Access Program (the “NIH EAP”) for CNM-Au8 treatment of amyotrophic lateral sclerosis (“ALS”), and was awarded under the Accelerating Access to Critical Therapies for ALS Act. On April 3, 2024, the Company entered into a grant subaward agreement (the “Subaward”) with Colombia pursuant to the NIH Grant.
 
The Subaward includes reimbursement of Company expenses for the NIH EAP in an amount up to $7.3 million during the period from September 25, 2023 to August 31, 2024. Disbursement of funds for the NIH EAP will be paid to the Company based on the Company’s submission of invoices to Colombia for reimbursement on a monthly or quarterly basis.
 
Of the $45.1 million total award, subawards to the Company under the NIH Grant may total up to $30.9 million in aggregate, inclusive of the Subaward, and may extend to August 31, 2027 and will be governed by future agreements or addendums.
 
Either Colombia or the Company may terminate the Subaward with 30 days written notice. Notwithstanding, if NIH terminates the NIH Grant, Colombia will terminate the Subaward in accordance with the NIH requirements.
 
In the performance of the Subaward, the Company may use background intellectual property, which it developed at private expense prior to the Subaward, including certain inventions and related technical data (the “Background IP”). However, the Company (i) does not and will not grant any licenses to Colombia or the U.S. Government in the Background IP, either express or implied; and (ii) none of the Background IP or any improvements thereto shall be considered an invention made in the performance of the Subaward. The Company is not required to deliver any Background IP or any other proprietary data under the Subaward until and unless the recipient agrees to safeguards for the protection of the confidentiality of the data that are satisfactory to the Company.
 
The foregoing description of the Subaward does not purport to be complete and is qualified in its entirety by reference to the text of the Subaward, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit Number  
Exhibit Description
10.1  
104  
Cover Page Interactive Data File (formatted as Inline XBRL).
 
1
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
 
     
 
CLENE INC.
   
Date: April 9, 2024
By:
/s/ Robert Etherington
   
Robert Etherington
   
President and Chief Executive Officer
 
2
 
 EX-10.1 2 ex_651360.htm EXHIBIT 10.1 HTML Editor

Exhibit 10.1

  

  SAPO: G18548 & G18549
FDP Cost Reimbursement Subaward
Federal Awarding Agency:  National Institute of Health (NIH)
Pass-Through Entity (PTE):  The Trustees of Colombia University in the City of New York Subrecipient:  Clene Nanomedicine Inc
PTE PI:  Jinsy Andrews Sub PI:  Benjamin Greenberg
PTE Federal Award No:  1U01NS136023-01 Subaward No:  2(GG011355-01)
Project Title:  Intermediate-sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS)
Subaward Budget Period: Amount Funded This Action (USD):  $7348370
Start:  09/25/2023 End:  08/31/2024  
Estimated Period of Performance: Incrementally Estimated Total (USD):  $30895644
Start:  09/25/2023 End:  08/31/2027  
 
Terms and Conditions
 
1. PTE hereby awards a cost reimbursable subaward (as determined by 2 CFR 200.331), to Subrecipient. The Statement of Work and budget for this Subaward are as shown in Attachment 5. In its performance of Subaward work, Subrecipient shall be an independent entity and not an employee or agent of PTE.
 
2. Subrecipient shall submit invoices not more often that monthly and not less frequently than quarterly for allowable costs incurred. Upon the receipt of proper invoices, the PTE agrees to process payments in accordance with this Subaward and 2 CFR 200.305. All invoices shall be submitted using Subrecipient’s standard invoice, but at a minimum shall include current and cumulative costs (including cost sharing), breakdown by major cost category, Subaward number, and certification, as required in 2 CFR 200.415(a). Invoices that do not reference PTE Subaward number shall be returned to Subrecipient. Invoices and questions concerning invoice receipt or payments shall be directed to the party’s Financial Contact, shown in Attachment 3A.
 
3. A final statement of cumulative costs incurred, including cost sharing, market “FINAL,” must be submitted to PTE’s Financial Contact, as shown in Attachment 3A, not later than 60 days after each Budget Period end date. The final statement of costs shall constitute Subrecipient’s final financial report.
 
4. All payments shall be considered provisional and are subject to adjustment within the total estimated cost in the event such adjustment is necessary as a result of an adverse audit finding against the Subrecipient.
 
5. Matters concerning the technical performance of this Subaward shall be directed to the appropriate party’s Principal Investigator as shown in Attachments 3A and 3B. Technical reports are required as shown in Attachment 4.
 
6. Matters concerning the request or negotiation of any changes in the terms, conditions, or amounts cited in this Subaward, and any changes requiring prior approval, shall be directed to the PTE’s Administrative Contact and the Subrecipient’s Administrative Contact show in Attachments 3A and 3B. Any such change made to this Subaward requires the written approval of each party’s Authorized Official as shown in Attachments 3A and 3B.
 
7. The PTE may issue non-substantive changes to the Budget Period(s) and Budget Bilaterally. Unilateral modification shall be considered valid 14 days after receipt unless otherwise indicated by Subrecipient when sent to Subrecipient’s Administrative Contact, as show in Attachment 3B.
 
8. Each party shall be responsible for its negligent acts or omissions and the negligent acts or omissions of its employees, officers, or directors, to the extent allowed by law.
 
9. Either party may terminate this Subaward within 30 days written notice. Notwithstanding, if the Awarding Agency terminates the Federal Award, PTE will terminate in accordance with the Awarding Agency requirements. PTE notice shall be directed to the Administrative Contact, and Subrecipient notice shall be directed to the Administrative Contact as shown in Attachments 3A and 3B. PTE shall pay Subrecipient for termination costs as allowable under Uniform Guidance, 2 CFR 200, or 45 CFR Part 75 Appendix IX, as applicable.
 
10. By signing this Subaward, including the attachments hereto which are hereby incorporated by reference, Subrecipient certifies that it will perform the Statement of Word in accordance with the terms and conditions of this Subaward and the applicable terms of the Federal Award, including the appropriate Research Terms and Conditions (“RTCs”) of the Federal Awarding Agency, as referenced in Attachment 2. The parties further agree that they intend this subaward to comply with all applicable laws, regulations, and requirements.
 
By an Authorized Official of the PTE: By an Authorized Official of the Subrecipient:
 /s/ William J Berger                4/3/2024            /s/ Rob Etherington                4/3/2024          
Name:  William J Berger Date Name: Rob Etherington Date
Title: Assistant Vice President   Title: CEO, Clene Inc.  

 

 
 

Attachment 1

Certifications and Assurances

 

[Omitted pursuant to Regulation S-K, Item 601(a)(5). We agree to furnish supplementally a copy of such omitted materials to the SEC upon request.]

 
 
        Attachment 2  

Subaward Number

    
        Federal Award Terms and Conditions   2(GG011355-01)    
                   
Required Data Elements   Awarding Agency Institute (If Applicable)  
  The data elements required by Uniform    
  Guidance are incorporated in the attached Federal Award. Federal Award Issue Date FAIN Assistance Listing No.  
                   
This Subaward Is:     Assistance Listing Program Title (ALTP)  
☒ Research & Development ☒ Subject to FFATA    
            Key Personnel Per NOA  
               
 
 
General Terms and Conditions
 
By signing this Subaward, Subrecipient agrees to the following:
 
1. To abide by the conditions on activities and restrictions on expenditure of federal funds in appropriations acts that are applicable to this Subaward to the extent those restrictions are pertinent. This includes any recent legislation noted on the Federal Awarding Agency’s website: http://grants.nih.gov/policy/notices.htm
 
2. 2 CFR 200 and 45 CFR Part 75.
 
3. The Federal Awarding Agency’s grants policy guidance, including addenda in effect as of the beginning date of the period of performance or as amended found at: http://grants.nih.gov/grants/policy/nihgps/nihgps.pdf
 
4. Research Terms and Conditions, including any Federal Awarding Agency’s Specific Requirements found at: https://www.nsf.gov/awards/managing/rtc.jsp
 
  a. No-cost extensions require the written approval of the PTE. Any requests for a no-cost extension shall be directed to the Financial Contact shown in Attachment 3A, not less than 30 days prior to the desired effective date of the requested change.
 
  b. Any payment mechanism and financial reporting requirements described in the applicable Federal Awarding Agency Terms and Conditions and Agency-Specific Requirements are replaced with Terms and Conditions (1) through (4) of this Subaward; and
 
  c. Any prior approvals are to be sought from the PTE and not the Federal Awarding Agency.
 
  d. Title to equipment as defined in 2 CFR 200.1 that is purchased or fabricated with research funds or Subrecipient cost sharing funds, as direct costs of the project or program, shall vest in the Subrecipient subject to the conditions specified in 2 CFR 200.313.
 
  e. Prior approval must be sought for a change in Subrecipient PI or change in Key Personnel (defined as listed on the NOA).
 
5. Treatment of program income: Additive
 
 
Special Terms and Conditions:
 
  Data Sharing and Access:
  Subrecipient agrees to comply with the Federal Awarding Agency’s data sharing and/or access requirements as reflected in the NOA or the Federal Awarding Agency’s standard terms and conditions as referenced in the General Terms and Conditions 1-4 above.
  No additional requirements
   
  Data Rights:
  Subrecipient grants to PTE the right to use data created in the performance of this Subaward solely for the purpose of an only to the extent required to meet PTE’s obligations to the Federal Government under its PTE Federal Award.
   
  Copyrights:
  Subrecipient Grants to PTE an irrevocable, royalty-free, non-transferable, non-exclusive right and license to use, reproduce, make derivative works, display, and perform publicly any copyrights or copyrighted material (including any computer software and its documentation and/or databases) first developed and delivered under this Subaward solely for the purpose of and only to the extent required to meet PTE’s obligations to the Federal Government under its PTE Federal Award.
   
  Subrecipient grants to PTE the right to use any written progress reports and deliverables created under this Subaward solely for the purpose of and only to the extent required to meet PTE’s obligations to the Federal Government under its Federal Award.
   
  Promoting Objectivity in Research (COI):
  Subrecipient must designate herein which entity’s Financial Conflicts of Interest policy (COI) will apply: Subrecipient
   
  If applying its own COI policy, by execution of this Subaward, Subrecipient certifies that its policy complies with the requirements of the relevant Federal Awarding Agency as identified herein: NIH - 42 CFR Part 50 Subpart F
   
  Subrecipient shall report any financial conflict of interest to PTE’s Administration Representative or COI contact, as designated on Attachment 3A. Any financial conflicts of interest identified shall, when applicable, subsequently be reported to Federal Awarding Agency. Such report shall be made before expenditure of funds authorized in this Subaward and within 45 days of any subsequently identified COI.
 
 
Work Involving Human or Vertebrate Animals (Select Applicable Options)
☐ No Human or Vertebrate Animals    
☒ Human Subjects IRB Upon Request
       
☐ Vertebrate Animals    
 
The PTE requires verification of IRB and/or IACUC approval be sent to the Administrative Contact as required above:
 
Subrecipient agrees that any non-exempt human and/or vertebrate animal research protocol conducted under this Subaward shall be reviewed and approved by the appropriate Institutional Review Board (IRB) and/or its Institutional Animal Care and Use Committee (IACUC), as applicable and that it will maintain current and duly approved research protocols for all periods of the Subaward involving human and/or vertebrate animal research. Subrecipient certifies that the appropriate IRB and/or IACUC are in full compliance with applicable state and federal laws and regulations. The Subrecipient certifies that any submitted IRB / IACUC approval represents a valid, approved protocol that is entirely consistent with the Project associated with this Subaward. In no event shall Subrecipient invoice or be reimbursed for any human or vertebrate animals related expenses incurred in a period where any applicable IRB / IACUC approval is not properly in place.
 
 
Human Subjects Data (Select One)  Human subjects data will not be addressed in this agreement
 
 
This section left intentionally blank
 
 
 
 
NIH Terms and Conditions
 
  The Clinical Trial Indicator in Section IV of the PTE’s NOA is stated as:  Yes
  The work being conducted by this subrecipient per this agreement is a clinical trial.
 
Multiple PIs (MPI)
 
  This subaward is subject to an MPI Leadership Plan. Both parties will follow the finalized MPI Leadership Plan.
  The MPI plan is attached as part of Attachment 6.
 
Certificate of Confidentiality:
 
The Parties agree that this research funded in whole or in part by the National Institutes of Health (“NIH”), is subject to NIH Policy NOT-OD-17-109 (the “Policy”) and therefore is deemed under the Policy to be issued a Certificate of Confidentiality (“Certificate”) should the conditions outlined within the Policy apply. Accordingly, the subrecipients who collect or receive identifiable, sensitive information are is required to adhere to the Policy and protect the privacy of individuals who are subjects of such research in accordance with the Policy and subsection 301(d) of the Public Health Service Act (the “PHS Act”).
 
 
Additional Terms
 

This Subaward supersedes all prior agreements, terms, conditions, and understandings, whether oral or written.

 

Pursuant to 2 C.F.R. § 315(c) the provisions of 37 C.F.R. § 401.14, Standard Patent Rights Clause, apply to this Subaward except that in that clause the term “Contractor” shall mean “Subrecipient.”

In the performance of this Subaward, Subrecipient may use background intellectual property, which it developed at private expense prior to the Subaward, including the inventions listed in Attachment Six hereto and related technical data (the “Background IP”). However, Subrecipient (1) does not and will not grant any licenses to the PTE or the Government in the Background IP, either express or implied; and (2) none of the inventions listed in Attachment Six or any improvements thereto shall be considered an invention made in the performance of the Subaward under 37 C.F.R. § 401.14 (i.e., a “Subject Invention”). Subrecipient is not required to deliver any Background IP or any other proprietary data hereunder until and unless the recipient agrees to safeguards for the protection of the confidentiality of the data that are satisfactory to Subrecipient.

 

 
 
 

Attachment 3A

Research Subaward Agreement

Pass-Through Entity (PTE) Contacts

 

[Omitted pursuant to Regulation S-K, Item 601(a)(5). We agree to furnish supplementally a copy of such omitted materials to the SEC upon request.]

 
 

Attachment 3B

Research Subaward Agreement

Subrecipient Contacts

 

[Omitted pursuant to Regulation S-K, Item 601(a)(5). We agree to furnish supplementally a copy of such omitted materials to the SEC upon request.]

 
 

Attachment 4

Reporting and Prior Approval Terms

 

[Omitted pursuant to Regulation S-K, Item 601(a)(5). We agree to furnish supplementally a copy of such omitted materials to the SEC upon request.]

 
 

Attachment 5

Statement of Work, Cost Sharing, Indirects & Budget

 

[Omitted pursuant to Regulation S-K, Item 601(a)(5). We agree to furnish supplementally a copy of such omitted materials to the SEC upon request.]

 
 

Attachment 6

Notice of Award (NOA) and any additional documents

 

[Omitted pursuant to Regulation S-K, Item 601(a)(5). We agree to furnish supplementally a copy of such omitted materials to the SEC upon request.]

 
 EX-101.SCH 3 clnn-20240403.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 clnn-20240403_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 clnn-20240403_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key Class of Stock [Axis] Class of Stock [Domain] CommonStock00001ParValue Custom [Member] WarrantsToAcquireOnehalfOfOneShareOfCommonStockFor1150PerShare Custom [Member] EX-101.PRE 6 clnn-20240403_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document And Entity Information
Apr. 03, 2024
Document Information [Line Items]  
Entity, Registrant Name CLENE INC.
Document, Type 8-K
Document, Period End Date Apr. 03, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-39834
Entity, Tax Identification Number 85-2828339
Entity, Address, Address Line One 6550 South Millrock Drive, Suite G50
Entity, Address, City or Town Salt Lake City
Entity, Address, State or Province UT
Entity, Address, Postal Zip Code 84121
City Area Code 801
Local Phone Number 676-9695
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001822791
CommonStock00001ParValue Custom [Member]  
Document Information [Line Items]  
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol CLNN
Security Exchange Name NASDAQ
WarrantsToAcquireOnehalfOfOneShareOfCommonStockFor1150PerShare Custom [Member]  
Document Information [Line Items]  
Title of 12(b) Security Warrants, to acquire one-half of one share of Common Stock for $11.50 per share
Trading Symbol CLNNW
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 3 22 1 false 2 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.clnn.com/20240403/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports clnn-20240403.xsd clnn-20240403_def.xml clnn-20240403_lab.xml clnn-20240403_pre.xml clnn20240409_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "clnn20240409_8k.htm": { "nsprefix": "clnn", "nsuri": "http://www.clnn.com/20240403", "dts": { "schema": { "local": [ "clnn-20240403.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "clnn-20240403_def.xml" ] }, "labelLink": { "local": [ "clnn-20240403_lab.xml" ] }, "presentationLink": { "local": [ "clnn-20240403_pre.xml" ] }, "inline": { "local": [ "clnn20240409_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://www.clnn.com/20240403/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "clnn20240409_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "clnn20240409_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "clnn_CommonStock00001ParValueCustomMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clnn.com/20240403", "localname": "CommonStock00001ParValueCustomMember", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "CommonStock00001ParValue Custom [Member]" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "clnn_WarrantsToAcquireOnehalfOfOneShareOfCommonStockFor1150PerShareCustomMember": { "xbrltype": "domainItemType", "nsuri": "http://www.clnn.com/20240403", "localname": "WarrantsToAcquireOnehalfOfOneShareOfCommonStockFor1150PerShareCustomMember", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "WarrantsToAcquireOnehalfOfOneShareOfCommonStockFor1150PerShare Custom [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.clnn.com/20240403/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001437749-24-011545-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-011545-xbrl.zip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clnn20240409_8k_htm.xml IDEA: XBRL DOCUMENT 0001822791 2024-04-03 2024-04-03 0001822791 clnn:CommonStock00001ParValueCustomMember 2024-04-03 2024-04-03 0001822791 clnn:WarrantsToAcquireOnehalfOfOneShareOfCommonStockFor1150PerShareCustomMember 2024-04-03 2024-04-03 false 0001822791 8-K 2024-04-03 CLENE INC. DE 001-39834 85-2828339 6550 South Millrock Drive, Suite G50 Salt Lake City UT 84121 801 676-9695 false false false false Common Stock, $0.0001 par value CLNN NASDAQ Warrants, to acquire one-half of one share of Common Stock for $11.50 per share CLNNW NASDAQ false